Literature DB >> 21643724

An atypical degenerative osteoarthropathy in Hyp mice is characterized by a loss in the mineralized zone of articular cartilage.

Guoying Liang1, Joshua Vanhouten, Carolyn M Macica.   

Abstract

Patients with X-linked hypophosphatemia (XLH) develop enthesophytes and osteophytes secondary to articular cartilage degeneration and together are the primary cause of morbidity in adult patients so afflicted. We have previously characterized the enthesopathy in Hyp mice, a murine model of XLH. We now extend these studies to the synovial joint in order to characterize potential cellular changes in articular cartilage that may predispose patients to the osteoarthropathy of XLH. We report that, despite highly elevated levels of alkaline phosphatase activity throughout articular cartilage, there is a complete loss in the mineralized zone of articular cartilage as assessed by von Kossa staining of mineral and as quantified by EPIC-microCT analysis and evidence of vascular invasion. We also identify the downregulation of extracellular matrix (ECM) factors identified as regulators of terminally differentiated mineralizing articular chondrocytes. There is also a striking increase in the histochemical staining of sulfated proteoglycans, a change that may reflect the loss of a transitional tissue that reduces mechanical stress at the interface between cartilage and subchondral bone. The failure of mineralizing articular chondrocytes to develop in the hypophosphatemic state suggests that phosphate may be a key regulator of chondrocyte mineralization. Accordingly, we find that the appropriate zonal arrangement and phenotypic markers of articular cartilage are significantly reestablished by phosphate-replacement therapy. Given the turnover and maintenance of articular cartilage ECM, the identification of early and abnormal cellular changes unique to XLH will undoubtedly aid in a more effective management of this disease to minimize the onset of degenerative osteoarthropathy.

Entities:  

Mesh:

Year:  2011        PMID: 21643724     DOI: 10.1007/s00223-011-9502-4

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  14 in total

Review 1.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

2.  FGF2 High Molecular Weight Isoforms Contribute to Osteoarthropathy in Male Mice.

Authors:  Patience Meo Burt; Liping Xiao; Caroline Dealy; Melanie C Fisher; Marja M Hurley
Journal:  Endocrinology       Date:  2016-10-12       Impact factor: 4.736

Review 3.  Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Authors:  Bracha K Goldsweig; Thomas O Carpenter
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

4.  Contrast-enhanced microCT (EPIC-μCT) ex vivo applied to the mouse and human jaw joint.

Authors:  G A P Renders; L Mulder; A S Lin; G E J Langenbach; J H Koolstra; R E Guldberg; V Everts
Journal:  Dentomaxillofac Radiol       Date:  2013-12-18       Impact factor: 2.419

5.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

6.  Phlpp1 facilitates post-traumatic osteoarthritis and is induced by inflammation and promoter demethylation in human osteoarthritis.

Authors:  E W Bradley; L R Carpio; M E McGee-Lawrence; C Castillejo Becerra; D F Amanatullah; L E Ta; M Otero; M B Goldring; S Kakar; J J Westendorf
Journal:  Osteoarthritis Cartilage       Date:  2015-12-31       Impact factor: 6.576

7.  Inhibition of FGFR Signaling Partially Rescues Osteoarthritis in Mice Overexpressing High Molecular Weight FGF2 Isoforms.

Authors:  Liping Xiao; Donyell Williams; Marja M Hurley
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

8.  Joint replacement in X-linked hypophosphatemia.

Authors:  Emily S Mills; Louis Iorio; Richard S Feinn; Kevin M Duignan; Carolyn M Macica
Journal:  J Orthop       Date:  2018-12-21

9.  Vibrational spectroscopic analysis of hydroxyapatite in HYP mice and individuals with X-linked hypophosphatemia.

Authors:  Eva Amenta; Helen E King; Holger Petermann; Vuk Uskoković; Steven M Tommasini; Carolyn M Macica
Journal:  Ther Adv Chronic Dis       Date:  2018-10-11       Impact factor: 5.091

10.  Giving Credence to the Experience of X-Linked Hypophosphatemia in Adulthood: An Interprofessional Mixed-Methods Study.

Authors:  Melissa Hughes; Carolyn Macica; Catherine Meriano; Maya Doyle
Journal:  J Patient Cent Res Rev       Date:  2020-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.